Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb (BMY)
NYSE:BMY
BMY Stock Chart & Stats
$55.99
-$0.69(-1.21%)
At close: 4:00 PM EST
$55.99
-$0.69(-1.21%)
Day’s Range― - ―
52-Week Range$42.52 - $63.33
Previous CloseN/A
Volume3.98M
Average Volume (3M)11.41M
Market Cap
$113.78B
Enterprise Value$149.30B
Total Cash (Recent Filing)$16.50B
Total Debt (Recent Filing)$51.04B
Price to Earnings (P/E)18.9
Beta0.27
Next Earnings
Feb 05, 2026EPS Estimate
1.23Next Dividend Ex-DateN/A
Dividend Yield4.84%
Share Statistics
EPS (TTM)1.63
Shares Outstanding2,035,753,000
10 Day Avg. Volume11,370,542
30 Day Avg. Volume11,412,684
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)7.02
Price to Sales (P/S)2.37
P/FCF Ratio8.22
Enterprise Value/Market Cap1.31
Enterprise Value/Revenue3.11
Enterprise Value/Gross Profit4.72
Enterprise Value/Ebitda10.02
Forecast
1Y Price Target
$57.59Price Target Upside2.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Alzheimer's Program DifferentiationAn Alzheimer's‑related psychosis candidate that may offer a safer alternative to current high‑risk treatments could capture a large unmet market and differentiate the franchise.
Clinical CatalystsMultiple pivotal late-stage trial readouts across the hematology and oncology pipeline could materially de‑risk programs and prompt a re‑rating of the stock.
New Product LaunchesRecently launched products are ramping and delivering meaningful commercial sales that can help stabilize revenue as legacy products face pressure.
Bears Say
Launch Performance And Labeling RiskPrescription volumes for a new antipsychotic remain below prior peaks and lack of adjunctive labeling is constraining physician adoption, raising the risk of a weaker-than-expected launch.
Patent ExpirationsImpending loss of exclusivity on key products is likely to pressure revenue and create continued downside risk for earnings.
Revenue Forecast UncertaintyRevisions to discounting and inventory assumptions are increasing uncertainty around revenue projections, complicating near-term financial visibility.
Bristol-Myers Squibb News
BMY FAQ
What was Bristol-Myers Squibb’s price range in the past 12 months?
Bristol-Myers Squibb lowest stock price was $42.52 and its highest was $63.33 in the past 12 months.
What is Bristol-Myers Squibb’s market cap?
Bristol-Myers Squibb’s market cap is $113.78B.
When is Bristol-Myers Squibb’s upcoming earnings report date?
Bristol-Myers Squibb’s upcoming earnings report date is Feb 05, 2026 which is tomorrow.
How were Bristol-Myers Squibb’s earnings last quarter?
Bristol-Myers Squibb released its earnings results on Oct 30, 2025. The company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.518 by $0.112.
Is Bristol-Myers Squibb overvalued?
According to Wall Street analysts Bristol-Myers Squibb’s price is currently Undervalued.
Does Bristol-Myers Squibb pay dividends?
Bristol-Myers Squibb pays a Quarterly dividend of $0.62 which represents an annual dividend yield of 4.84%. See more information on Bristol-Myers Squibb dividends here
What is Bristol-Myers Squibb’s EPS estimate?
Bristol-Myers Squibb’s EPS estimate is 1.23.
How many shares outstanding does Bristol-Myers Squibb have?
Bristol-Myers Squibb has 2,035,753,000 shares outstanding.
What happened to Bristol-Myers Squibb’s price movement after its last earnings report?
Bristol-Myers Squibb reported an EPS of $1.63 in its last earnings report, beating expectations of $1.518. Following the earnings report the stock price went up 7.102%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb?
Currently, no hedge funds are holding shares in BMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bristol-Myers Squibb Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$57.59 (2.86% Upside)
$57.59 (2.86% Upside)
Blogger Sentiment
Bullish
BMY Sentiment 87%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.6%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.40%
12-Months-Change
Fundamentals
Return on Equity
33.84%
Trailing 12-Months
Asset Growth
3.44%
Trailing 12-Months
Company Description
Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
BMY Company Deck
BMY Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook with strong growth in the portfolio, increased revenue guidance, and successful business development activities. However, there remain challenges with the adoption of new products like Cobenfy and the uncertainty surrounding IRA negotiations.View all BMY earnings summariesBMY Revenue Breakdown
46.71% Growth Portfolio
53.29% Legacy Portfolio
BMY Stock 12 Month Forecast
Average Price Target
$57.59
▲(2.86% Upside)
Technical Analysis
Ownership Overview
0.05% Insiders
19.74% Mutual Funds
0.16% Other Institutional Investors
53.78% Public Companies and Individual Investors